BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGUANGZHOU, CHINA, January 5, 2018 – Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies as well as a pipeline of biosimilars, today announced that Bert Thomas, PhD, MBA, Bio-Thera’s Senior Vice President of Business Development, ...
Recently, t he Antibody-Drug Conjugates (ADCs) program’s‘Recombinant Humanized anti-HER2 Monoclonal Antibody-Maytansine Conjugates for Injection’ (BAT8001) was approved for clinical trials in China. BAT8001 is suitable for multiple cancer disease indications, including HER2 over-expressed meta...
On September 5 2016,Bio-thera reached a strategic cooperation agreement with world class CRO, Quintiles. Under agreement with Bio-Thera, Quintileswith provide all-around international clinicalstudy and filingcooperative supportfor new drugs developed by Bio-thera. The signing ceremony was held at th...